Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CD69 | Q07108 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30955 | 0.75 | — | — | |
| Bromide SCHEMBL899944 | 0.74 | ALDH1A1 (0.34) | MAPTALDH1A1USP2HPGDTDP1 | |
| SCHEMBL8716884 | 0.72 | TSHR (0.50) | MAPTNAMPTCYP1A2DRD2DRD1 | |
| SCHEMBL8853321 | 0.72 | — | — | |
| SCHEMBL5516098 | 0.72 | — | — | |
| Ammonia Solution, Strong SCHEMBL897323 | 0.72 | — | — | |
| SCHEMBL3971014 | 0.71 | NAMPT (0.52) | NAMPT | |
| Oxybate SCHEMBL8707092 | 0.69 | CAMK2A (0.58) | MAPTADRA1AALDH1A1TDP1L3MBTL1 | |
| SCHEMBL28541225 | 0.68 | CYP1A2 (0.42) | MAPTADRA1AALDH1A1CYP1A2DRD2 | |
| Alcohol SCHEMBL15798418 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414833-B1 | NOVEL TRANSITION-METAL COMPLEXES AND USE THEREOF IN TRANSITION-METAL CATALYSED REACTIONS | SALTIGO GMBH (DE) | 2010-06-16 | — | — | EP | disclosed |
| US-20040176608-A1 | Novel transition-metal complexes and use thereof in transition-metal catalyzed reactions | BAYER CHEMICALS AG (DE) | 2004-09-09 | — | — | US | disclosed |
| EP-1414833-A1 | NOVEL TRANSITION-METAL COMPLEXES AND USE THEREOF IN TRANSITION-METAL CATALYSED REACTIONS | Bayer Chemicals AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011875-A1 | NOVEL TRANSITION-METAL COMPLEXES AND USE THEREOF IN TRANSITION-METAL CATALYSED REACTIONS | BAYER CHEMICALS AG (DE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176608-A1 | Novel transition-metal complexes and use thereof in transition-metal catalyzed reactions | AP1M1, SOD1, INTS9 | MAPT 2516/4885NAMPT 2267/4885ADRA1D 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.